KR100417287B1 - Composition for treating diabetes comprising a lower alcohol insoluble extract from hovenia dulcis thunberg. or a polysaccharide isolated therefrom - Google Patents
Composition for treating diabetes comprising a lower alcohol insoluble extract from hovenia dulcis thunberg. or a polysaccharide isolated therefrom Download PDFInfo
- Publication number
- KR100417287B1 KR100417287B1 KR1020020057998A KR20020057998A KR100417287B1 KR 100417287 B1 KR100417287 B1 KR 100417287B1 KR 1020020057998 A KR1020020057998 A KR 1020020057998A KR 20020057998 A KR20020057998 A KR 20020057998A KR 100417287 B1 KR100417287 B1 KR 100417287B1
- Authority
- KR
- South Korea
- Prior art keywords
- kda
- polysaccharide
- arabinose
- mannose
- molecular weight
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 81
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 62
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 56
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 244000010000 Hovenia dulcis Species 0.000 title claims abstract description 15
- 235000008584 Hovenia dulcis Nutrition 0.000 title claims abstract description 15
- 150000004676 glycans Chemical class 0.000 title claims abstract 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract description 79
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 150
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 59
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 59
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 50
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 38
- 239000008103 glucose Substances 0.000 claims abstract description 38
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 34
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 34
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 28
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 21
- 229930182830 galactose Natural products 0.000 claims abstract description 21
- -1 ramanose Chemical compound 0.000 claims abstract description 19
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 48
- 239000011780 sodium chloride Substances 0.000 claims description 24
- 235000013399 edible fruits Nutrition 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000002023 wood Substances 0.000 claims description 20
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003456 ion exchange resin Substances 0.000 claims description 10
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 235000010955 Hovenia acerba Nutrition 0.000 claims description 4
- 241001533134 Hovenia acerba Species 0.000 claims description 4
- 235000009229 Hovenia trichocarpa Nutrition 0.000 claims description 4
- 241000724121 Hovenia trichocarpa Species 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 241000566916 Tomentella Species 0.000 claims description 2
- 235000002597 Solanum melongena Nutrition 0.000 claims 5
- 244000061458 Solanum melongena Species 0.000 claims 5
- 238000003808 methanol extraction Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 150000004804 polysaccharides Chemical class 0.000 description 35
- 239000000243 solution Substances 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 12
- 230000002218 hypoglycaemic effect Effects 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 229960001052 streptozocin Drugs 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 239000003729 cation exchange resin Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 229940023913 cation exchange resins Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000000569 multi-angle light scattering Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XDIYNQZUNSSENW-NUVHGKSTSA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanal;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-NUVHGKSTSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000002211 ultraviolet spectrum Methods 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241000238814 Orthoptera Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000011358 absorbing material Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000018927 edible plant Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- DPEYHNFHDIXMNV-UHFFFAOYSA-N (9-amino-3-bicyclo[3.3.1]nonanyl)-(4-benzyl-5-methyl-1,4-diazepan-1-yl)methanone dihydrochloride Chemical compound Cl.Cl.CC1CCN(CCN1Cc1ccccc1)C(=O)C1CC2CCCC(C1)C2N DPEYHNFHDIXMNV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241000233839 Commelina communis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000008955 Dioscorea japonica Species 0.000 description 1
- 235000005251 Dioscorea japonica Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 235000008559 Hovenia tomentella Nutrition 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 241000985694 Polypodiopsida Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940127024 acid based drug Drugs 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000012461 cellulose resin Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940105922 elm extract Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000026313 regulation of carbohydrate metabolic process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
당뇨병은 혈당 조절 호르몬인 인슐린이 제대로 만들어지지 않거나 작용을 하지 못하여 발병하는 질환으로, 음식물의 대사에 의해 생성된 포도당이 세포 내로이동되지 못하고 그대로 혈액 속에 남아 고혈당 상태를 초래하고, 이로 인해 다음(多飮), 다뇨(多尿), 다식(多食)의 3대 증상이 나타나며, 다양한 합병증이 수반된다. 그러므로 혈액 내의 포도당(혈당) 함량을 낮추어 주는 것은 당뇨병에서 당뇨합병증으로 인한 여러 가지 질환을 예방하는데 중요한 요소이다.Diabetes mellitus is a disease caused by the inability of insulin, a blood glucose control hormone, to function properly. Glucose produced by food metabolism does not move into cells and remains in the blood, resulting in high blood sugar levels.飮), multi urine (多 尿), multi-diet (多 食) three symptoms appear, accompanied by various complications. Therefore, lowering the glucose (blood sugar) content in the blood is an important factor in preventing various diseases caused by diabetic complications in diabetes.
당뇨병은 가장 일반적인 내분비질환으로 현재 우리 나라의 환자 수는 200만명으로서 30대 이상 인구의 11%가 환자로 추정되는 대표적인 성인병이다. 당뇨병은 탄수화물 대사의 조절을 포함한 여러 가지 세포내외의 환경에서 대사성 이상을 초래하고, 이들 이상은 시각계, 신경계, 비뇨계, 맥관계 등과 같은 여러 장기에서 병변을 일으킨다. 당뇨병은 주로 2가지 형태로 구분할 수 있는데 인슐린 의존형(제1형) 당뇨병은 환경적 요인으로 유전적 소인이 활성화되어 인슐린을 생산하는 베타세포에 자기면역반응을 일으켜 유발된다고 알려져 있다. 인슐린 비의존형 당뇨병(제2형)은 그 병인이 명확하지는 않으나 인슐린 저항성의 증가가 중요한 원인으로 알려져 있다.Diabetes is the most common endocrine disorder, and the current number of patients in Korea is 2 million, representing 11% of the population aged over 30. Diabetes causes metabolic abnormalities in a variety of intracellular and external environments, including the regulation of carbohydrate metabolism, and these abnormalities cause lesions in many organs such as the visual, nervous, urinary, and pulmonary systems. Diabetes can be classified into two types. Insulin-dependent (type 1) diabetes is known to be caused by an autoimmune response to insulin-producing beta cells by genetic predisposition as an environmental factor. Insulin-independent diabetes mellitus (type 2) is not known for its etiology, but an increase in insulin resistance is known to be an important cause.
당뇨병 치료제로는 인슐린이 가장 이상적이고 효능적이나 그 지속시간이 짧고 경구적으로는 작용을 나타내지 못하므로 주사제로 사용하여야 하는 단점이 있다. 현재까지 사용되고 있는 경구용 혈당강하제로는 설폰요산계(sulphonylurea) 및 비구아니드(biguanide)계 약물이 있다. 설폰요산계 약물은 췌장의 베타세포에서 만들어진 인슐린의 분비를 촉진시켜 혈당강하작용을 나타내나, 간독성 및 저혈당을 야기한다. 또한, 비구아니드계 약물은 오심, 식욕부진, 설사 등의 부작용을 나타낸다. 따라서 이러한 부작용을 감소시킬 수 있는 다른 기전의 경구용 당뇨치료제 개발이 요구되고 있다.Insulin is the most ideal and effective way to treat diabetes, but its duration is short and it does not show oral action. Oral hypoglycemic agents used to date include sulfonyl-urea and biguanide-based drugs. Sulfonic acid-based drugs promote the secretion of insulin produced by the beta cells of the pancreas, thereby lowering blood glucose levels, but causing hepatotoxicity and hypoglycemia. In addition, biguanide-based drugs have side effects such as nausea, anorexia and diarrhea. Therefore, there are other mechanisms that can reduce these side effects. Development of oral diabetes treatments is required.
당뇨병은 치료하기 어려운 질병으로 약물치료와 함께 식이요법이 절대적으로 필요하다. 또한 기존의 인슐린이나 경구 혈당 강하제의 투여로는 근원적 치료에 한계가 있고 경제적 부담과 더불어 부작용의 위험도 수반하고 있어, 근래에 와서는 오랫동안 민간 약용으로 쓰여 온 야생식용식물의 혈당강하효과에 대한 관심이 증대되고 이 분야에 대한 많은 연구가 수행되고 있다.Diabetes is a difficult disease to treat and absolutely requires diet along with medication. In addition, the administration of insulin or oral hypoglycemic agents is limited in the fundamental treatment, and accompanied by the economic burden and the risk of side effects. Recently, attention has been paid to the hypoglycemic effect of wild edible plants for a long time as a folk medicine. There is an increasing amount of research in this area.
이 등(Lee M. Y. 등(1988),J. Korean Soc. Food Nutr.17, 57-61)의 실험에서도 두릅나무 추출물이 혈당강하 효과를 보였으며, 오미자의 에테르-메탄올 추출물이 알록산(alloxan)으로 당뇨병이 유발된 토끼에서 강력한 혈당강하 작용을 나타낸다는 것이 확인되었다(Sheo H. J. 등(1987),J. Korean Soc. Food Nutr.16, 262-267). 또한 닭의 장풀(Commelina communisL.)과 참마(Dioscorea japonicaThunb)가 스트렙토조토신(streptozotocin, STZ) 유발 당뇨 흰쥐에서 혈당 강하 효과가 있음이 보고된 바 있다(Lim S. J. 및 Kim M. W.(1992),Korean J. Nutr.25, 511-517). 그 외에도 메밀 급여가 스트렙토조토신 유발 당뇨 흰쥐의 혈중 포도당과 콜레스테롤 함량을 감소시켰다는 연구보고도 있다(Lee J. S.(1994),한국영양학회지27, 819-827). 또한 천연물로부터 분리한 다당체를 이용한 연구들이 진행되고 있는데, 동충하초 배양액으로부터 분리한 다당체(CS-F10)의 구조 및 이 다당체가 STZ에 의한 당뇨쥐와 에피네프린(epinephrine)에 의한 고혈당 쥐에서 혈당강하에 대한 활성을 가지고 있음이 보고된 바 있고(Tadashi K. 등(1999),Biol. Pharm. Bull.22:966-970), 목이버섯으로부터 분리한 산성다당체(TAP)와 그의분해산물(TAP-H)의 항당뇨효과, 즉 이들이 STZ에 의한 당뇨쥐의 혈당, 인슐린량, 콜레스테롤 함량, 중성지질 그리고 지질과산화를 감소시킨다는 것이 보고된 바 있다(Tadashi K. 등(2001),Biol. Pharm. Bull24:1400-1403).Lee, et al. (1988), J. Korean Soc. Food Nutr. 17, 57-61) showed that the elm extract showed hypoglycemic effect, and the ether-methanol extract of Schisandra chinensis was alloxan. It has been confirmed that diabetes mellitus has a potent hypoglycemic effect (Sheo HJ et al. (1987), J. Korean Soc. Food Nutr. 16, 262-267). In addition, it has been reported that Commelina communis L. and Yam ( Dioscorea japonica Thunb) have hypoglycemic effects in streptozotocin (STZ) -induced diabetic rats (Lim SJ and Kim MW (1992), Korean J. Nutr. 25, 511-517 ). In addition, buckwheat supplementation has been shown to reduce blood glucose and cholesterol levels in streptozotocin-induced diabetic rats (Lee JS (1994), Korean Journal of Nutrition , 27, 819-827). In addition, studies using polysaccharides isolated from natural products have been conducted. It has been reported to have activity (Tadashi K. et al. (1999), Biol. Pharm. Bull. 22: 966-970), acidic polysaccharides (TAP) and their degradation products (TAP-H) isolated from sour mushrooms Have been reported to reduce the anti-diabetic effects of diabetes mellitus, STZ-induced blood sugar, insulin, cholesterol, triglyceride and lipid peroxidation (Tadashi K. et al. (2001), Biol. Pharm. Bull 24: 1400-1403).
이에 본 발명자들은 여러 종류의 천연물을 대상으로 하여 당뇨병 예방 및 치료에 유용한 활성이 기대되는 식물을 탐색하는 과정에서 헛개나무(Hovenia dulcisThunberg.)의 저급 알콜 불용성 추출 분획 및 그로부터 분리된 다당체가 우수한 혈당 강하 활성을 나타냄을 발견하였다.Therefore, the inventors of the present invention target low alcohol insoluble extract fraction of Hovenia dulcis Thunberg. And the polysaccharides isolated therefrom in the process of searching for plants that are expected to be useful for preventing and treating diabetes against various kinds of natural products. It was found to exhibit lowering activity.
상기 문헌들을 포함한 선행기술들은 여러 야생 식용 식물 추출물을 대상으로 당뇨병 치료 효과를 보고하고 있으나, 헛개나무의 추출물이 혈당 강하 효과를 갖는다는 것에 대하여는 지금까지 보고된 바가 전혀 없다.Prior arts, including the above documents, have reported the effects of treating diabetes on various wild edible plant extracts, but there has been no report on the fact that the extract of the liana has a hypoglycemic effect.
헛개나무(Hovenia dulcisThunb.)는 갈매나무과 낙엽활엽 교목으로 경기, 강원 이남의 표고 50-800 m에 분포하고 있으며, 일본, 중국에도 분포하고 있다. 또한 한국, 중국, 일본에는Hovenia dulcisThunb.(한국, 일본, 중국; 꽃은 연녹색, 잎에는 털이 없다)라는 기본 종 외에 그 변종들인Hovenia dulcisvar.latifoliaNakai.(일본특산 동북지방;Hovenia dulcis에 비해 잎이 대단히 크다),Hovenia dulcisvar.koreanaNakai(한국특산; 꽃은 백색이다) 그리고,Hovenia dulcisvar.tomentellaMakino(일본특산 본주, 사국; 잎에 털이 있다)가 분포하고 있다. Hovenia dulcis Thunb. Is a buckthorn and deciduous broad-leaved arbor tree that is distributed at 50-800 m above sea level in Gyeonggi and south of Gangwon. It is also distributed in Japan and China. In addition to the basic species Hovenia dulcis Thunb. (Korea, Japan, China; the flowers are light green, the leaves have no hair), the varieties Hovenia dulcis var. latifolia Nakai. (Japanese specialty Northeast; leaves are very large compared to the Hovenia dulcis), Hovenia dulcis var. koreana Nakai (specialty of Korea; the flower is white) and Hovenia dulcis var. Tomentella Makino (Japanese native sake, four countries; hair on leaves) is distributed.
본 발명의 목적은 당뇨병 예방 및 치료에 유용한 헛개나무 잎의 저급알콜 불용성 추출물을 제공하는 것이다.It is an object of the present invention to provide a lower alcohol insoluble extract of foliar leaves useful for preventing and treating diabetes.
본 발명의 다른 목적은 헛개나무의 저급알콜 불용성 추출물 및 이로부터 분리된 활성 다당체 분획을 포함하는 당뇨병의 예방 및 치료용 약학 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of diabetes, comprising a low alcohol insoluble extract of the larvae and an active polysaccharide fraction isolated therefrom.
본 발명의 또 다른 목적은 상기 헛개나무 잎의 저급알콜 불용성 추출물을 유효성분으로 하고 식품학적으로 허용되는 첨가제를 포함하는 당뇨 예방용 건강보조식품을 제공하는 것이다.Still another object of the present invention is to provide a dietary supplement for preventing diabetes comprising a low alcohol insoluble extract of the foliar leaves as an active ingredient and a food acceptable additive.
도 1은 헛개나무 목질부로부터 메탄올 불용성 추출 분획 및 고분자 분획을 분리하는 과정을 나타낸 것이고,Figure 1 shows the process of separating the methanol insoluble extraction fraction and the polymer fraction from the bark wood part,
도 2는 헛개나무 어린 가지로부터 메탄올 불용성 추출 분획 및 고분자 분획을 분리하는 과정을 나타낸 것이고,Figure 2 shows the process of separating the methanol insoluble extraction fraction and the polymer fraction from the bark young branches,
도 3은 헛개나무 과병으로부터 메탄올 불용성 추출 분획 및 고분자 분획을 분리하는 과정을 나타낸 것이고,Figure 3 shows the process of separating the methanol insoluble extraction fraction and the polymer fraction from the fruit tree fruit trees,
도 4는 헛개나무 잎으로부터 메탄올 불용성 추출 분획 및 고분자 분획을 분리하는 과정을 나타낸 것이고,Figure 4 shows the process of separating the methanol insoluble extract fraction and the polymer fraction from the leaves of the bark,
도 5는 헛개나무 목질부로부터 얻은 메탄올 불용성 분획의 RI 및 UV 스펙트럼이고,5 is RI and UV spectra of methanol insoluble fractions obtained from lumber wood,
도 6은 헛개나무 어린 가지로부터 얻은 메탄올 불용성 분획의 RI 및 UV 스펙트럼이고,FIG. 6 is RI and UV spectra of methanol insoluble fractions obtained from larvae spp.,
도 7은 헛개나무 과병으로부터 얻은 메탄올 불용성 분획의 RI 및 UV 스펙트럼이고,FIG. 7 is RI and UV spectra of methanol insoluble fractions obtained from a ragweed fruit disease,
도 8은 스트렙토조토신(STZ)으로 당뇨가 유발된 쥐의 시간 경과에 따른 체중변화를 나타낸 것이고,Figure 8 shows the weight change over time of the mice induced diabetes with streptozotocin (STZ),
도 9는 스트렙토조토신으로 당뇨가 유발된 쥐의 시간 경과에 따른 사료소비량을 나타낸 것이고,Figure 9 shows the feed consumption of the streptozotocin-induced diabetic rats over time,
도 10은 당뇨가 유발된 대조군 및 헛개나무 부위별 추출물 투여군의 쥐에서 혈장 포도당 함량을 나타낸 것이고,10 shows the plasma glucose content in the rats of the diabetic-induced control group and the extract-administered group of the larvae,
도 11은 당뇨가 유발된 대조군 및 헛개나무 부위별 추출물 투여군의 쥐에서 혈장 단백질 함량을 나타낸 것이고,Figure 11 shows the plasma protein content in the rats of the diabetic-induced control group and the extract-administered group according to the larvae,
도 12는 당뇨가 유발된 대조군 및 헛개나무 부위별 추출물 투여군의 쥐에서 혈장 알부민 함량을 나타낸 것이고,Figure 12 shows the plasma albumin content in the rats of the diabetic-induced control group and the extract-administered group of the larvae,
도 13은 당뇨가 유발된 대조군 및 헛개나무 부위별 추출물 투여군의 쥐에서 혈장 요소 함량을 나타낸 것이다.Figure 13 shows the plasma urea content in the rats of the diabetic-induced control group and the extract-administered group according to the larvae.
상기 목적에 따라, 본 발명에서는 헛개나무 (Hovenia dulcis Thunb.)의 음건한 잎을 열수 가압 또는 저급알콜로 추출하여 얻어진 열수 또는 저급알콜 추출액에 저급알콜을 가하여 얻어지는 저급알콜 불용성 추출물을 제공한다.In accordance with the above object, the present invention provides a lower alcohol insoluble extract obtained by adding a lower alcohol to the hot water or lower alcohol extract obtained by extracting the dry leaves of the bark (Hovenia dulcis Thunb.) By hot water pressurization or lower alcohol.
본 발명에서 "저급알콜"이란 메탄올, 메탄올 수용액, 에탄올, 에탄올 수용액, 노말프로판올, 이소-프로판올, 노말 부탄올, 또는 이들의 혼합물로부터 선택된 임의의 알콜을 말한다."Lower alcohol" as used herein refers to any alcohol selected from methanol, aqueous methanol solution, ethanol, aqueous ethanol solution, normal propanol, iso-propanol, normal butanol, or mixtures thereof.
본 발명의 헛개나무는 한국산 (Hovenia dulcisvar. Korean Nakai.), 일본산 (Hovenia dulcisvar. tomentella Makino) 및 중국산 (Hovenia acerbaLindl.,Hovenia acerbavar. kiukiangensis C. Y. WU,Hovenia trichocarpaChun et Tsiang,Hovenia trichocarpavar. fulvotomemtosa) 헛개나무를 모두 포함한다.Heotgae tree of the present invention, Korean (Hovenia dulcis var. Korean Nakai. ), Japanese (Hovenia dulcis var. Tomentella Makino) and Chinese (Hovenia acerba Lindl., Hovenia acerba var. Kiukiangensis CY WU, Hovenia trichocarpa Chun et Tsiang, Hovenia trichocarpa var.fulvotomemtosa) Contains all of the holly.
본 발명의 저급알콜 불용성 추출물은 1) 헛개나무 잎으로부터 가압 열수 또는 저급알콜 추출물을 얻는 단계; 및 2) 상기 추출물에 저급알콜을 첨가하여 저급알콜 불용성 추출물을 얻는 단계를 포함하는 방법에 의하여 제조될 수 있다.The lower alcohol insoluble extract of the present invention comprises the steps of 1) obtaining pressurized hot water or lower alcohol extract from the leaves of the liana; And 2) adding a lower alcohol to the extract to obtain a lower alcohol insoluble extract.
단계 1)에서는 헛개나무의 잎을 가압 열수 또는 저급알콜 추출방법에 따라 추출할 수 있는데, 예를 들어, 가압 열수 추출방법은 헛개나무 잎의 부피에 대하여 약 1 내지 5배, 바람직하게는 3배의 물을 가하고, 약 1 내지 3기압, 바람직하게는 1.5 기압에 해당하는 압력으로 약 110 내지 150℃, 바람직하게는 120 내지 125℃에서 15분 내지 48시간, 바람직하게는 30분 내지 12시간 동안 추출한 후에, 이를 상온에서 방치하여 식힌 다음, 여과하여 얻은 여액을 통상의 동결건조방법에 따라 동결 건조하여 가압 열수 분획 추출물을 얻을 수 있다. 또한, 저급알콜 추출방법은 헛개나무 잎의 부피에 대하여 2 내지 10배, 바람직하게는 3내지 7배의 저급알콜을 가하고 20 내지 80℃, 바람직하게는 25 내지 50℃로 가열하면서 5분 내지 3시간 동안, 바람직하게는 10 내지 1시간 동안 초음파 추출하고 냉각 및 여과한 후 회전증발기로 감압농축하여 헛개나무 목질부로부터 저급알콜 추출물을 얻으며, 이때 여과 후 남은 잔사에 대하여 여과 과정을 2회 이상 반복하여 실시할 수 있다. 추출용매인 저급알콜로는 메탄올, 메탄올 수용액, 에탄올, 에탄올 수용액, 노말프로판올, 이소-프로판올, 노말 부탄올, 또는 이들의 혼합물이 사용될 수 있으며, 70 내지 100 % 의 메탄올이 가장 바람직하다.In step 1), the leaves of the barn tree can be extracted according to the pressurized hot water or lower alcohol extraction method, for example, the pressurized hot water extraction method is about 1 to 5 times, preferably 3 times the volume of the barn tree leaves. Water is added, and the pressure corresponds to about 1 to 3 atmospheres, preferably 1.5 atmospheres, for about 15 to 48 hours, preferably 30 to 12 hours at about 110 to 150 ℃, preferably 120 to 125 ℃ After extraction, the mixture is left to stand at room temperature, cooled, and the filtrate obtained by filtration is lyophilized according to a conventional freeze-drying method to obtain a pressurized hydrothermal fraction extract. In addition, the lower alcohol extraction method is added to 2 to 10 times, preferably 3 to 7 times lower alcohol relative to the volume of the bark leaves and 5 to 3 minutes while heating to 20 to 80 ℃, preferably 25 to 50 ℃ For a period of time, preferably 10 to 1 hours, ultrasonic extraction, cooling and filtration, and concentrated under reduced pressure with a rotary evaporator to obtain a lower alcohol extract from the wood of the bark tree, wherein the filtration process is repeated two or more times for the remaining residue after filtration It can be carried out. As the lower alcohol as the extraction solvent, methanol, aqueous methanol solution, ethanol, aqueous ethanol solution, normal propanol, iso-propanol, normal butanol, or a mixture thereof may be used, with 70 to 100% methanol being most preferred.
단계 2)에서는 상기로부터 얻어진 가압 열수 또는 저급알콜 추출물을 상온에서 건조 또는 감압 농축한 후 상기 농축물을 저급알콜, 바람직하게는 100 % 메탄올로 30분 내지 3시간, 바람직하게는 10분 내지 1시간 동안, 3 내지 4회 환류 추출하여 얻어진 환류 추출액을 다시 원심분리하여 저급알콜 불용성 분획을 모아 저급 알콜 불용성 분획을 얻는다. 또는, 상기 환류 추출액을 여과하고 여과되지 않은 불용성 분획에 2 내지 8배, 바람직하게는 약 4배 부피의 저급 알콜, 바람직하게는 100 % 에탄올을 첨가하여 상등액과 침전물을 분리하고, 그 침전물에 증류수를 가해 재용해한 후, 이를 동결건조하여 저급 알콜 불용성 분획을 얻을 수 있다.In step 2), the pressurized hot water or lower alcohol extract obtained from the above is dried or concentrated under reduced pressure at room temperature, and the concentrate is then lowered to 30 minutes to 3 hours, preferably 10 minutes to 1 hour with lower alcohol, preferably 100% methanol. During this, the reflux extract obtained by reflux extraction 3 to 4 times was centrifuged again to collect the lower alcohol insoluble fraction to obtain a lower alcohol insoluble fraction. Alternatively, the reflux extract is filtered and the supernatant and the precipitate are separated by adding 2-8 times, preferably about 4 times the volume of lower alcohol, preferably 100% ethanol, to the unfiltered insoluble fraction and distilled water to the precipitate. After redissolution by addition, it can be lyophilized to obtain a lower alcohol insoluble fraction.
헛개나무의 다른 부위의 저급알콜 불용성 추출물들은 상기 잎 추출물의 제조방법과 동일한 방법에 따라 헛개나무의 목질부, 어린 가지 및 과병 등으로부터 제조할 수 있다. 헛개나무의 어린 가지로는 1 내지 4년생의 어린 가지를 사용하는 것이 바람직하다.Lower alcohol insoluble extracts of other parts of the bark tree may be prepared from woody parts, young branches and fruit diseases of the bark tree according to the same method as the method of preparing the leaf extract. It is preferable to use young branches of 1 to 4 years as young branches of the barn.
또한, 상기 저급알콜 불용성 추출물을 이온 교환수지 컬럼 크로마토그래피로 분리하는 단계를 포함하는 방법에 의하여 다당체 분획들을 제조할 수 있다.In addition, polysaccharide fractions may be prepared by a method comprising the step of separating the lower alcohol insoluble extract by ion exchange resin column chromatography.
예를 들어, 상기의 저급알콜 불용성 추출물을 증류수에 녹인 후, 0 내지 5 M의 염화나트륨 수용액을 농도 단계별로 이온 교환수지 컬럼에 넣어 차례로 용출시킨 후, 투석, 농축 및 동결건조를 차례로 수행하여 각 농도별로 고분자의 다당체 성분으로 구성된 고분자 분획물들을 얻는다. 이때, 이온 교환수지는 양이온 교환수지 또는 음이온 교환수지를 사용할 수 있으며, 바람직한 양이온 교환수지로는 AG 50W-x8, 앰버라이트 (Amberlite) IR-120, 도웩스 (Dowex) 50W-x8 등과 같은 강산성 양이온 교환수지; 앰버라이트 IRC-50, 바이오-렉스 (Bio-Rex) 70, 듀올라이트 (Duolite)-436 등과 같은 약산성 양이온 교환수지; 앰버라이트 IRA-67, 도웩스 3-x4A 등과 같은 약염기성 양이온 교환수지; AG 2x8, 앰버라이트 IRA-400, 도웩스 2-x8 계열 등과 같은 강염기성 양이온 교환수지; 또는 CM-셀룰로오스, SE-셀룰로오스와 같은 양이온 교환수지, DEAE 셀룰로오스와 같은 음이온 교환수지와 같은 개량된 섬유성 셀룰로오스로 이루어진 교환수지; 또는 가교 결합된 덱스트란으로 제조되는, 예를 들어, G-25 및 G-50 비드형 양이온 세파덱스형 수지, 아가로즈로 제조되는, 예를 들어, 세파로즈 CL 및 바이오겔 A 세파로즈형 수지 또는 프락토겔 (Fractogels)이나 토요펄 (Toyopearl) 수지와 같은 개량된 비드형 이온 교환수지가 적합하며, 더욱 바람직한 수지는 약염기성 음이온 교환수지인 토요펄 DEAE형 교환수지이고, 가장 바람직한 수지는 토요펄 DEAE-650C형 교환수지이다.For example, after dissolving the lower alcohol insoluble extract in distilled water, 0 to 5 M aqueous sodium chloride solution was added to the ion exchange resin column in concentration step by step, followed by dialysis, concentration, and lyophilization in turn to perform each concentration. To obtain a polymer fraction consisting of a polysaccharide component of the star. At this time, the ion exchange resin may be a cation exchange resin or an anion exchange resin, a preferred cation exchange resin strong acid cations such as AG 50W-x8, Amberlite IR-120, Doex 50W-x8 Exchange resin; Weakly acidic cation exchange resins such as Amberlite IRC-50, Bio-Rex 70, Duoolite-436 and the like; Weakly basic cation exchange resins such as amberlite IRA-67, Dow's 3-x4A and the like; Strongly basic cation exchange resins such as AG 2x8, Amberlite IRA-400, Dowks 2-x8 series, and the like; Or exchange resins consisting of improved fibrous celluloses such as cation exchange resins such as CM-cellulose, SE-cellulose, and anion exchange resins such as DEAE cellulose; Or made of crosslinked dextran, eg, G-25 and G-50 beaded cation Sephadex-type resins, eg agarose, eg Sepharose CL and Biogel A Sepharose-type resins Or improved bead type ion exchange resins, such as Fractogels or Toyopearl resins, more preferred resins are Toyopearl DEAE type exchange resins, which are weakly basic anion exchange resins, the most preferred being Pearl DEAE-650C type exchange resin.
상기 이온 교환수지를 통하여 헛개나무 목질부의 저급알콜 불용성 추출물로부터 분리되는 다당체로서, 염화나트륨의 농도에 따라, O M 염화나트륨 용액에서는 만노즈, 글루코즈, 갈락토즈, 라마노즈, 아라비노즈, 자일로즈로 구성된 분자량 5,750 내지 5,760 kDa의 고분자성 다당체, 0.1 M 염화나트륨 용액에서는 만노즈, 글루코즈, 갈락토즈, 라마노즈, 아라비노즈, 자일로즈로 구성된 분자량 21,500 내지 21,600 kDa의 고분자성 다당체, 0.2 M 염화나트륨 용액에서는 만노즈, 글루코즈, 라마노즈, 아라비노즈, 자일로즈로 구성된 분자량 285 내지 286 kDa의 고분자성 다당체, 0.3 M 염화나트륨 용액에서는 만노즈, 글루코즈, 갈락토즈, 아라비노즈, 자일로즈로 구성된 분자량 62.7 내지 62.8 kDa 및 40.6 내지 40.7 kDa의 고분자성 다당체, 3 M 염화나트륨 용액에서는 만노즈, 글루코즈, 갈락토즈, 아라비노즈, 자일로즈로 구성된 분자량 37.7 내지 37.8 kDa의 고분자성 다당체가 용출된다.The polysaccharide is separated from the lower alcohol insoluble extract of the wood of the bark wood through the ion exchange resin, depending on the concentration of sodium chloride, in the OM sodium chloride solution, the molecular weight of 5,750 consisting of mannose, glucose, galactose, ramanose, arabinose, xylose High molecular weight polysaccharides of 21,500 to 21,600 kDa consisting of mannose, glucose, galactose, ramanose, arabinose, xylose in the polymer polysaccharide of 0.1 to 5,760 kDa, sodium chloride, mannose, glucose in the 0.2 M sodium chloride solution , 285 to 286 kDa molecular weight polysaccharide consisting of ramanose, arabinose, xylose, 0.3 M sodium chloride solution, 62.7 to 62.8 kDa and 40.6 to 40.7 consisting of mannose, glucose, galactose, arabinose, xylose Polymeric polysaccharide of kDa, mannose in 3 M sodium chloride solution, gluco , Galactose, arabinose, a polymeric polysaccharide having a molecular weight of 37.7 to 37.8 kDa composed of xylene and elute rose.
또한, 헛개나무 어린 가지의 저급알콜 불용성 추출물로부터 분리되는 다당체로서, O M 염화나트륨 용액에서는 만노즈, 글루코즈, 갈락토즈. 아라비노즈, 자일로즈로 구성된 분자량 68.0 내지 68.1 kDa 및 36.4 내지 36.5 kDa의 고분자성 다당체, 0.1 M 염화나트륨 용액에서는 만노즈, 글루코즈, 라마노즈,아라비노즈로 구성된 분자량 22 내지 23 kDa; 233 내지 234 kDa; 및 200 내지 201 kDa의 고분자성 다당체, 0.2 M 염화나트륨 용액에서는 만노즈, 라마노즈, 아라비노즈, 자일로즈로 구성된 분자량 32.8 내지 32.9 kDa의 고분자성 다당체, 0.3 M 염화나트륨 용액에서는 만노즈, 글루코즈, 아라비노즈로 구성된 분자량은 88.6 내지 88.7 kDa 및 79.1 내지 79.2 kDa의 고분자성 다당체가 용출되며, 3 M 염화나트륨 용액에서는 만노즈, 갈락토즈, 아라비노즈, 자일로즈로 구성된 분자량 216 내지 217 kDa의 고분자성 다당체가 용출된다.Also, it is a polysaccharide isolated from the lower alcohol insoluble extracts of the bark sprigs, and in the O M sodium chloride solution, mannose, glucose, galactose. Arabinose, a molecular weight of 68.0 to 68.1 kDa consisting of xylose and 36.4 to 36.5 kDa of a polymeric polysaccharide, a molecular weight of 22 to 23 kDa consisting of mannose, glucose, lamanose, arabinose in a 0.1 M sodium chloride solution; 233 to 234 kDa; And a polymeric polysaccharide of 200 to 201 kDa, a molecular polysaccharide having a molecular weight of 32.8 to 32.9 kDa consisting of mannose, ramanose, arabinose and xylose in a 0.2 M sodium chloride solution, mannose, glucose and arabinose in a 0.3 M sodium chloride solution. The molecular weight consisting of 88.6 to 88.7 kDa and 79.1 to 79.2 kDa of the polymer polysaccharide is eluted, and in the 3 M sodium chloride solution, the polymer polysaccharide of 216 to 217 kDa molecular weight consisting of mannose, galactose, arabinose, xylose elutes do.
헛개나무 과병의 저급알콜 불용성 추출물로부터 분리되는 다당체로서, 0 M 염화나트륨 용액에서는 만노즈, 글루코즈, 갈락토즈, 아라비노즈, 자일로즈로 구성된 분자량 1,330 내지 1,340 kDa의 고분자성 다당체, 0.1 M 염화나트륨 용액에서는 만노즈, 글루코즈, 갈락토즈, 라마노즈, 아라비노즈, 자일로즈로 구성된 분자량 142 내지 143 kDa의 고분자성 다당체, 0.2 M 염화나트륨 용액에서는 만노즈, 글루코즈, 갈락토즈, 라마노즈, 아라비노즈로 구성된 분자량 70.5 내지 70.6 kDa의 고분자성 다당체, 0.3 M 염화나트륨 용액에서는 만노즈, 글루코즈, 갈락토즈, 라마노즈, 아라비노즈, 자일로즈로 구성된 분자량 102 내지 103 kDa의 고분자성 다당체, 3 M 염화나트륨 용액에서는 만노즈, 글루코즈, 아라비노즈로 구성된 분자량 5.0 내지 5.5 kDa의 고분자성 다당체가 용출된다.A polysaccharide isolated from the lower alcohol insoluble extracts of the liana, a high molecular weight polysaccharide of 1,330 to 1,340 kDa consisting of mannose, glucose, galactose, arabinose, and xylose in 0 M sodium chloride solution, and only in 0.1 M sodium chloride solution. Polymeric polysaccharide of molecular weight 142 to 143 kDa consisting of nose, glucose, galactose, ramanose, arabinose and xylose, molecular weight consisting of mannose, glucose, galactose, lamanose and arabinose in a 0.2 M sodium chloride solution Polymeric polysaccharide of 70.6 kDa, polymeric polysaccharide of molecular weight 102-103 kDa consisting of mannose, glucose, galactose, lamanose, arabinose, xylose in 0.3 M sodium chloride solution, mannose, glucose, in 3 M sodium chloride solution A high molecular weight polysaccharide of 5.0 to 5.5 kDa composed of arabinose is eluted.
그러나 본 발명의 목적에 부합하는 헛개나무의 저급알콜 추출물로부터 분리되는 다당체는 상기한 염화나트륨의 다양한 농도에 따라 용출되는 다당체들 뿐만 아니라, 분자량 20 kDa 이상의 모든 다당체들을 포함한다.However, polysaccharides isolated from the lower alcohol extracts of the bark tree in accordance with the object of the present invention include all polysaccharides having a molecular weight of 20 kDa or more, as well as the polysaccharides eluted according to the various concentrations of sodium chloride described above.
상기 방법에 따라 헛개나무의 목질부, 어린 가지, 과병 및 잎으로부터 얻은 저급알콜 불용성 추출물, 및 이들로부터 분리된 활성 다당체 분획들은 당뇨가 유발된 동물에서 혈당을 강하시키고, 혈장 단백질 및 알부민 함량을 정상에 가깝게 유지시키며, 당뇨에 수반하여 증가하는 혈장 요소 함량을 감소시키므로, 당뇨병의 예방 및 치료에 유용하게 사용될 수 있다.Lower alcohol insoluble extracts obtained from the woody parts, young branches, fruits and leaves of the larvae, and the active polysaccharide fractions isolated from them according to the method, lower blood sugar levels and increase the plasma protein and albumin content in normal diabetic animals. It keeps close, and decreases the plasma urea content that increases with diabetes, it can be useful for the prevention and treatment of diabetes.
이에 따라, 본 발명은 헛개나무의 목질부, 어린 가지, 과병 및 잎의 저급알콜 불용성 추출물, 및 이로부터 분리된 다당체 분획을 유효성분으로 하고 약학적으로 허용되는 담체를 포함하는 당뇨병의 예방 및 치료용 약학 조성물을 제공한다. 또한, 상기 헛개나무 잎의 저급알콜 불용성 추출물을 유효성분으로 하고 식품학적으로 허용되는 첨가제를 포함하는 당뇨 예방용 건강보조식품을 제공한다.Accordingly, the present invention is for the prevention and treatment of diabetes mellitus, including a low alcohol insoluble extract of the wood, young branches, fruit and leaves of the larvae, and a polysaccharide fraction isolated therefrom as an active ingredient and a pharmaceutically acceptable carrier. It provides a pharmaceutical composition. In addition, the low alcohol insoluble extract of the leaves of the bark tree as an active ingredient and provides a dietary supplement for preventing diabetes comprising a food-acceptable additive.
본 발명의 약학 조성물은 통상적으로 사용되는 부형제, 붕해제, 감미제, 활택제, 향미제 등을 추가로 포함할 수 있으며, 통상적인 방법에 의하여 정제, 캡슐제, 산제, 과립제, 현탁제, 유화제, 시럽제, 액제 또는 비경구 투여용 제제와 같은 단위 투여형 또는 수회 투여용 약제학적 제제로 제형화될 수 있다.The pharmaceutical composition of the present invention may further include excipients, disintegrants, sweeteners, lubricants, flavoring agents, etc. which are commonly used, tablets, capsules, powders, granules, suspensions, emulsifiers, It may be formulated in unit dosage form or in multiple dosage pharmaceutical formulations, such as syrups, solutions or parenteral preparations.
본 발명의 상기 저급알콜 불용성 추출물 또는 이로부터 분리된 다당체 분획을 함유한 약학 조성물은 목적하는 방법에 따라 비경구 투여하거나 경구 투여할 수 있으며, 하루에 유효성분으로서 헛개나무 추출물을 체중 1 ㎏당 0.001 내지 0.2 g바람직하게는 0.01 내지 0.05 g의 양을 1 내지 수회에 나누어 투여할 수 있다. 특정 환자에 대한 투여용량 수준은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율, 질환의 정도에 따라 변화될 수 있다.The lower alcohol insoluble extract of the present invention or the pharmaceutical composition containing the polysaccharide fraction isolated therefrom may be parenterally or orally administered according to the desired method, and the extract of the hawthorn tree as an active ingredient per day is 0.001 per kg of body weight To 0.2 g Preferably, the amount of 0.01 to 0.05 g can be administered in one to several times. Dosage levels for a particular patient may vary depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion, and degree of disease.
헛개나무 잎의 저급알콜 불용성 추출물은 당뇨병의 예방 및 치료의 목적으로 식품 또는 음료에 첨가될 수 있다. 이때, 상기 저급알콜 불용성 추출물은 일반적으로 건강식품 조성물에는 전체 식품 중량의 0.1 내지 15 중량%, 바람직하게는 1 내지 10 중량%로 첨가할 수 있으며, 건강음료 조성물에는 100 ㎖을 기준으로 1~30 g, 바람직하게는 3~10 g의 비율로 첨가할 수 있다.Lower alcohol insoluble extracts of the larvae leaves may be added to food or beverages for the purpose of preventing and treating diabetes. At this time, the lower alcohol insoluble extract is generally added to the health food composition 0.1 to 15% by weight, preferably 1 to 10% by weight of the total food weight, 1 to 30 based on 100 ml in the health beverage composition g, preferably 3 to 10 g.
본 발명의 건강보조식품은 지시된 비율로 필수성분으로서 상기 저급알콜 불용성 추출물을 함유하는 외에는 액체성분에 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 단당류, 예를 들어, 포도당, 과당 등; 이당류, 예를 들어 말토즈, 슈크로즈 등; 및 다당류, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리스리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제 (타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등), 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1~20 g, 바람직하게는 약 5~12 g이다.The dietary supplement of the present invention does not have any particular limitation on the liquid component except for containing the lower alcohol insoluble extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등),펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes a variety of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, colorants and neutralizers (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
건강보조식품 개발을 위하여 본 발명의 상기 저급알콜 불용성 추출물 및 다당체 분획을 첨가할 수 있는 식품으로는, 예를 들어 각종 식품류, 음료류, 껌류, 비타민 복합제 등이 있다.Examples of foods to which the lower alcohol insoluble extract and polysaccharide fraction of the present invention may be added for the development of dietary supplements include various foods, beverages, gums, vitamin complexes, and the like.
이하에서 본 발명을 실시예에 의거하여 보다 구체적으로 설명한다. 단, 이들 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명이 이들만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples. However, these Examples are only for illustrating the present invention, the present invention is not limited to these.
실시예 1: 헛개나무 각 부위의 저급알콜 불용성 추출물의 제조Example 1 Preparation of Lower Alcohol Insoluble Extracts of Each Part of Bare Tree
경기도 포천군 소홀면 직동리 국립수목원내에서 채취하여 음건한 헛개나무의 목질부, 어린 가지, 과병 및 잎 각 1 kg에 증류수 5 ℓ를 각각 넣고 120℃에서 3시간동안 고압(1.5 기압)하에서 열수추출기(합동정밀기공 HD5-A 190모델, 한국)로 가압열수 추출을 실시하였다. 추출액을 와트만 페이퍼(Whatman No. 2, 미국)로 여과시켜 얻은 추출물을 동결 건조기 (삼원냉열 SHDSM24L 모델, 한국)로 건조하여 헛개나무 목질부, 어린 가지, 과병 및 잎의 열수 추출물(각각 23.4g, 12.2g, 145.7g 및 158.3 g)을 제조하였다(도 1 내지 4 참조). 이어서 상기에서 얻어진 가압 열수 추출물을 상온에서 건조 또는 감압농축하고, 이 농축물을 100 % 메탄올로 1시간 동안 3 내지 4회 환류 추출하여 얻어진 환류 추출액을 다시 원심분리(5,000 rpm, 15분)하여 저급알콜 불용성 분획을 모아 저급 알콜 불용성 분획을 얻었다.5 liters of distilled water was added to 1 kg each of woody parts, young branches, fruit and leaves of the dry bark tree, and collected from the National Arboretum, Sohol-myeon, Pocheon-gun, Gyeonggi-do, Korea. Pressurized hot water extraction was carried out with precision pore HD5-A 190 model (Korea). The extract obtained by filtration of the extract with Whatman No. 2 (USA) was dried with a freeze dryer (three-way cold-heated SHDSM24L model, Korea), followed by hydrothermal extracts of bark wood, young branches, fruits and leaves (23.4g, respectively). 12.2 g, 145.7 g and 158.3 g) were prepared (see FIGS. 1-4). Subsequently, the pressurized hot water extract obtained above was dried or concentrated under reduced pressure at room temperature, and the reflux extract obtained by refluxing the concentrate with 100% methanol for 3 to 4 times for 1 hour was again centrifuged (5,000 rpm, 15 minutes) The alcohol insoluble fractions were collected to obtain a lower alcohol insoluble fraction.
실시예 2. 저급알콜 불용성 분획에 포함된 물질의 특성 분석Example 2 Characterization of Materials in Lower Alcohol Insoluble Fractions
(1)이온교환 컬럼 크로마토그래피법에 의한 고분자 분획의 정제 및 분리(1) Purification and Separation of Polymer Fractions by Ion Exchange Column Chromatography
실시예 1에서 얻은 헛개나무 목질부, 어린 가지, 과병 및 잎의 메탄올 불용성 분획으로 이온 교환 수지 컬럼 크로마토그래피법을 실시하였다. 메탄올 불용성 분획 1 g을 정제수 100 ㎖에 상온에서 30분간 교반기를 사용하여 녹였다. 탈염 증류수로 평형화시킨 토요펄(Toyo pearlR, 토소(Tosoh)사, 일본) DEAE-650C 이온 교환 수지 160 ㎖을 254 nm UV 측정기(제품명, 회사)와 RI 측정기(RI 모니터: RI-10 모델, EYELA사, 일본)가 설치된 저압 액체 크로마토그래피 시스템(Biologic LP, BIO-RAD 러보레이토리사, 미국)의 액체 크로마토그래피 컬럼(35cm 길이, 2.5cm 직경, Glass Econo-컬럼, BIO-RAD 러보레이토리사, 미국)에 충진시키고 다시 탈염 증류수 500 ㎖를 흘러 보내면서 평형화시켰다. 탈염 증류수에 용해된 메탄올 불용성 분획 100 ㎖를 컬럼의 DEAE-650C 수지 위에 가하고 흘려주어 흡착시켰다. 여기에 0 M, 0.1 M, 0.2 M, 0.3 M, 3 M의 NaCl 용액을 500 ㎖씩 2 ㎖/hr의 용출 속도로 흘려보내는 단계적 용출법에 의해 용출시켰다.Ion-exchange resin column chromatography was carried out with methanol insoluble fractions of the lumber, young branches, fruit and leaves obtained in Example 1. 1 g of methanol insoluble fraction was dissolved in 100 ml of purified water at room temperature for 30 minutes using a stirrer. Toyo pearl (Toyo pearl R , Tosoh, Japan) 160 ml of DEAE-650C ion exchange resin equilibrated with demineralized distilled water was added to a 254 nm UV meter (product name, company) and RI meter (RI monitor: RI-10 model, A liquid chromatography column (35 cm long, 2.5 cm diameter, Glass Econo-column, BIO-RAD Loveborito) of a low pressure liquid chromatography system (Biologic LP, BIO-RAD Rubberatorie, USA) with EYELA, Japan Lissa, USA) and equilibrated with 500 ml of demineralized distilled water again. 100 ml of methanol insoluble fraction dissolved in demineralized distilled water was added to the DEAE-650C resin in the column and flowed to adsorb. Here, 0 M, 0.1 M, 0.2 M, 0.3 M, and 3 M NaCl solutions were eluted by a stepwise elution method in which 500 ml were flowed at an elution rate of 2 ml / hr.
그 결과, 용출된 헛개나무 목질부 메탄올 불용성 분획물의 크로마토그램은 도 5에서와 같이 0.1 M 분획에서 UV에 흡광하는 물질들이 용출되기 시작해서, 0.3 M 분획 이후에 대부분이 용출되었고, RI에 흡광하는 물질들은 0.3 M 분획 이후부터 용출되기 시작하였다. 헛개나무 어린 가지 메탄올 불용성 분획물의 크로마토그램은 도 6에서와 같이 모든 용출 분획에서 UV에 흡광하는 물질들이 용출되었고, RI에 흡광하는 물질은 0.3M 분획 이후부터 용출되기 시작하였다. 헛개나무 과병 메탄올 불용성 분획물의 크로마토그램은 도 7에서와 같이 0.1 M 분획 이후에서부터 UV에 흡광하는 물질들이 용출되었고, RI에 흡광하는 물질은 0.3 M 분획 이후부터 용출되기 시작하였다. 헛개나무 목질부, 어린 가지, 과병 및 잎의 용출분획 중에 포함된 염화나트륨을 제거하기 위해서 각각을 분자량 컷-오프(cut-off) 치가 1,200 Da인 투석막(평균 편평 두께 32 mm, 용량 100 ml/ft 벤조일화 투석 튜빙, 시그마사, 미국)으로 4시간 동안 탈염 증류수로 3회 반복하여 투석한 다음, 동결건조기(삼원냉열 SFDSM24L, 한국)로 동결 건조하여 헛개나무 목질부, 어린 가지, 과병 및 잎의 메탄올 불용성 분획에서 고분자의 다당체 분획물들을 얻었다.As a result, the chromatogram of the methanol insoluble fraction of the elder tree was eluted with UV absorbing substances in the 0.1 M fraction, as shown in FIG. 5, and most of the eluted wood was eluted after the 0.3 M fraction. They began to elute after the 0.3 M fraction. Chromatograms of the methanol insoluble fraction of the hawthorn tree branch were eluted with UV absorbing materials in all the eluting fractions as shown in FIG. 6, and the materials absorbing RI began to elute after the 0.3M fraction. The chromatogram of the ethanol insoluble fraction of the ferns was eluted with UV absorbing material after 0.1 M fraction as shown in FIG. 7, and the material absorbing RI began to elute after 0.3 M fraction. Dialysis membranes with an average molecular weight cut-off of 1,200 Da (average flat thickness 32 mm, volume 100 ml / ft benzoyl) to remove sodium chloride contained in the elution fractions of the bark wood, young branches, fruit and leaves. Dialysis tubing, Sigma, USA) was dialyzed three times with demineralized distilled water for 4 hours and then lyophilized with a freeze dryer (Samwon cold-heat SFDSM24L, South Korea) to remove methanol insoluble in the woody parts of spruce, young branches, fruit and leaves. Polysaccharide fractions of the polymer were obtained in the fraction.
(2) SEC-HPLC-MALLS에 의한 절대분자량 측정(2) Absolute molecular weight measurement by SEC-HPLC-MALLS
펌프(Spectra system p2000), 가드 컬럼(TSK PWH, Tosoh사), RI-감지기(Shodex SE71), SEC(Size Exclusion Chromatography) 컬럼으로서 TSK 겔 3000pw, 4000pw, 5000pw(7.8×300mm, Tosoh) 및, MALLS(다각 레이저광 산란, DawnDSP-F, Wyatt Technology)) 검출기로 이루어진 기기 및 전개용매로서 0.02 % 소듐 아지드에 0.15 M의 NaNO3가 되게 만든 용액을 0.5 ㎖/분의 유속으로 흘려 보내 GPC를 실시함으로써 절대분자량을 측정하였다.TSK gel 3000pw, 4000pw, 5000pw (7.8 × 300mm, Tosoh) and MALLS as pump (Spectra system p2000), guard column (TSK PWH, Tosoh), RI-detector (Shodex SE71), SEC (Size Exclusion Chromatography) column (Polygonal Laser Scattering, DawnDSP-F, Wyatt Technology) A device consisting of a detector and a developing solvent, GPC was carried out by flowing a solution made to 0.15 M NaNO 3 in 0.02% sodium azide at a flow rate of 0.5 ml / min. Absolute molecular weight was measured by this.
그 결과, 표 1에서와 같이 목질부 메탄올 불용성 분획의 피크는 주로 5개로, 분획 1은 분자량이 5,758,000, 분획 2는 분자량이 21,520,000, 분획 3은 분자량이 285,000, 분획 4는 분자량이 40,620 및 62,720(평균분자량: 51,670), 분획 5는 분자량이 37,770로 확인되었다.As a result, as shown in Table 1, the peaks of the wood-insoluble methanol insoluble fraction are mainly five, fraction 1 has a molecular weight of 5,758,000, fraction 2 has a molecular weight of 21,520,000, fraction 3 has a molecular weight of 285,000, and fraction 4 has a molecular weight of 40,620 and 62,720 (average). Molecular weight: 51,670) and fraction 5 had a molecular weight of 37,770.
또한 표 2와 같이 어린 가지 메탄올 불용성 분획의 피크는 주로 9개로 분획 1은 분자량이 68,040 및 36,440(평균 분자량 52,240), 분획 2는 분자량이 22,500, 233,300, 200,700(평균 분자량: 228,250), 분획 3은 분자량이 32,840, 분획 4는 분자량이 88,610 및 79,190(평균 분자량: 83,900), 분획 5는 분자량이 216,500으로 확인되었다.In addition, as shown in Table 2, there are mainly 9 peaks of methanol insoluble fractions, and fraction 1 has 68,040 and 36,440 molecular weight (52,240 average molecular weight), fraction 2 has molecular weight of 22,500, 233,300, 200,700 (average molecular weight: 228,250), and fraction 3 The molecular weight was 32,840, fraction 4 was found to be 88,610 and 79,190 (average molecular weight: 83,900) and fraction 5 was 216,500.
그리고 표 3에서와 같이 과병 메탄올 불용성 분획의 피크는 주로 4개로 분획 1은 분자량이 1,330,000, 분획 2는 142,800, 분획 3은 분자량이 70,540, 분획 4는 102,400, 분획5는 5,300으로 확인되었다.As shown in Table 3, the peaks of the most insoluble methanol insoluble fraction were four, and fraction 1 was 1,330,000, fraction 2 was 142,800, fraction 3 was 70,540, fraction 4 was 102,400, and fraction 5 was 5,300.
상기 결과들로부터, 이온교환 크로마토그래피에 의해 용출된 분획들이 고분자성 물질임이 증명되었다.From the above results, it was proved that the fractions eluted by ion exchange chromatography were polymeric substances.
(3) 구성당 분석(3) analysis per composition
상기 각 분획들의 구성당 분석 및 확인을 위해서, 하꼬모리법 [Hakomori, S,J. Biochem. Tokyo,55, p205~209. 1964) 참조]과 웨게법 [Waeghe, T. J et al.,Carbohydr. Res.,123, p281~304. 1983) 참조]을 사용하여 메틸화 분석을 하였다. 즉, 시료(500 ㎍)의 메틸화 후, 에탄올을 흡착시킨 셉-팩 C18카트리지(Supelco사,미국)로 메틸화된 시료를 회수하였다. 메틸화 다당 중에서 산성당은 테트라하이드로푸란(THF)에 용해되어 있는 LiB(C2H5)3D (수퍼-듀프라이드, 1 ㎖, 상온, 1시간, 알드리히사)으로 환원시킨 후, 다시 셉-팩 C18카트리지로 회수하였다. 이를 1.0 M 트리플루오로아세트산(TFA)로 121℃에서 2시간동안 가수 분해한 후에 NaBD4로 환원시켜 아세틸화 반응을 수행하였다. 부분적으로 메틸화된 알디톨 아세테이트는 GC로 분석하였다. 메틸화된 알디톨 아세테이트들은 이온조각과 상대 용출시간으로 확인하고, 피크는 피크 면적과 FID(Flame ionization detector)의 반응 인자로 측정하였다.For analysis and confirmation of the composition of each fraction, the Hakomori method [Hakomori, S, J. Biochem. Tokyo , 55 , p205-209. 1964) and the Wege method [Waeghe, T. J et al., Carbohydr. Res. , 123 , p281-304. (1983) methylation analysis. That is, after methylation of the sample (500 µg), the methylated sample was collected by a Sep-Pak C 18 cartridge (Supelco, USA) in which ethanol was adsorbed. Acidic sugars in methylated polysaccharides are reduced to LiB (C 2 H 5 ) 3 D (super-dupride, 1 mL, room temperature, 1 hour, Aldrich) dissolved in tetrahydrofuran (THF) Recovered with a Pack C 18 cartridge. This was hydrolyzed with 1.0 M trifluoroacetic acid (TFA) at 121 ° C. for 2 hours and then reduced to NaBD 4 to carry out an acetylation reaction. Partially methylated alditol acetate was analyzed by GC. Methylated alditol acetates were identified by ion fragmentation and relative elution time, and the peaks were determined by the peak area and reaction factor of the flame ionization detector (FID).
또한 각 다당체 분획들의 구성당 분석을 위한 GC 분석은 바리안 CP-3800 가스 크로마토그래피기기를(Varian Co. 미국) 사용하여 다음의 조건으로 실시하였다:In addition, GC analysis for the compositional analysis of each polysaccharide fraction was carried out using a Varian CP-3800 gas chromatography device (Varian Co. USA) under the following conditions:
검출기: FIDDetector: FID
컬럼: 0.25mm ID 퓨즈드 실리카 캐필러리 GC 컬럼(30cm×0.25mm×0.2㎛; Supelco SP-2380)Column: 0.25 mm ID Fused Silica Capillary GC Column (30 cm × 0.25 mm × 0.2 μm; Supelco SP-2380)
컬럼온도: 230℃, 주입기 온도: 250℃, 검출기 온도: 250℃Column temperature: 230 ° C, injector temperature: 250 ° C, detector temperature: 250 ° C
이동상: 헬륨(1.0 ㎖/분).Mobile phase: helium (1.0 mL / min).
상기 실험 결과, 헛개나무의 목질부, 어린 가지 및 과병의 메탄올 불용성 분획으로부터 분리된 각 분획들의 구성당 조성(만노즈 1 기준)은 각각 하기 표 4 내지 6과 같았다.As a result of the experiment, the composition (mannose 1 basis) of each fraction separated from the methanol insoluble fraction of the bark, young branches and fruit of the larvae was as shown in Tables 4 to 6, respectively.
실시예 3: 헛개나무 저급알콜 불용성 추출물의 당뇨 억제 효과Example 3: Diabetes Inhibitory Effect of Low Alcohol Insoluble Extracts
(단계 1) 실험동물 사육 및 당뇨 유발(Step 1) Raising Laboratory Animals and Inducing Diabetes
스트렙토조토신(Streptozotocin(STZ))은 췌장의 베타세포에 선택적으로 세포독성을 나타내는 화합물로서, STZ으로 당뇨를 유발시킨 흰쥐를 당뇨 모델로 이용하여 혈당강하 효과에 관한 연구가 이루어지고 있다(Konno C. et al.,Planta medica51: 162-163 (1985); Hikino H. et al.,Planta Medica54: 1-3 (1988)).Streptozotocin (STZ) is a compound that selectively produces cytotoxicity against beta-cells in the pancreas, and studies have been conducted on hypoglycemic effects using STZ-induced diabetes as a diabetic model (Konno C). et al., Planta medica 51: 162-163 (1985); Hikino H. et al., Planta Medica 54: 1-3 (1988)).
갓 이유한 수컷 스프라그-다울리 쥐를 2~3주 동안 사료와 물을 자유섭취하게 하면서 사육한 후 체중이 200 ~ 300 g이 되면 1군당 10 마리씩 정상 대조군, 당뇨유발 대조군, 실시예 1에서 제조된 헛개나무 부위별(목부, 어린 가지, 과병 및 잎) 저급알콜 불용성 추출물을 처리할 시험군의 여섯 군으로 나누었다. 당뇨유발 대조군 및 시험군의 쥐들에게는 5 mM 시트레이트 완충액(citrate buffer, pH 4.5)에 녹인 STZ을 체중 kg당 60 mg의 용량으로 복강 내에 주사하여 당뇨병을 유발하였다. 정상 대조군에는 같은 부피의 시트레이트 완충액만을 주사하였다. STZ 투여 다음날부터 실험동물의 당뇨유발 유무를 확인하기 위해서 당뇨유발 군들에 대해 글루코테스트 스틱(Glucotest stick, 영동제약(주), UriscanTM)을 이용하여 뇨당 검사를 했다. STZ 투여 1주일 후부터 시험군의 쥐들에게는 물 대신 헛개나무 부위별 추출물을 0.5% 농도로 물에 녹여 마리당 100 ml씩 10일간 투여했다.Freshly weaned male Sprague-Dawley rats were fed with free feed and water for 2 to 3 weeks and then weighed 200 to 300 g per 10 rats per group in the normal control, diabetes-induced control, Example 1 The lower alcohol insoluble extracts prepared for each part of the barn wood prepared (neck, young branches, fruit and leaves) were divided into six groups of test groups to be treated. Diabetes-induced control and test groups of rats were induced by intraperitoneal injection of STZ dissolved in 5 mM citrate buffer (pH 4.5) at a dose of 60 mg / kg body weight. Normal controls received only the same volume of citrate buffer. In order to determine the presence of diabetic animals from the day after STZ administration using a test stick glucoside (Glucotest stick, gel Pharmaceuticals (share), Uriscan TM) for diabetic counties it had nyodang inspection. One week after the STZ administration, rats in the test group were dissolved in water at a concentration of 0.5% instead of water, and then administered 100 ml per horse for 10 days.
(단계 2) 항당뇨 효과 확인(Step 2) Check the antidiabetic effect
(2-1) 체중 및 사료섭취량의 분석(2-1) Analysis of body weight and feed intake
실험동물이 섭취한 사료량을 매일 일정한 시간에 측정하고, 또한 헛개나무 부위별 저급알콜 불용성 추출물 투여 첫날을 0일로 했을 때 8일 동안 매일 일정한 시간에 동물용 체중계(animal balance)로 체중을 측정함으로써 헛개나무 부위별 저급알콜 불용성 추출물 투여가 당뇨유발 쥐의 체중과 사료섭취량에 미치는 영향을 비교분석하였다.The amount of feed consumed by the test animals was measured at a certain time every day, and when the first day of administration of the low alcohol insoluble extract for each part of the bark tree was 0 days, the weight was measured with an animal balance at a certain time every day for 8 days. The effects of low alcohol insoluble extract on the body weight and feed intake of diabetic rats were compared.
그 결과, 체중의 경우에는 도 8에서 보듯이 8일째에 정상 대조군은 원래 체중보다 43.3 %가 증가하였고, 당뇨 유발 대조군은 13.9 % 감소하였으며, 헛개나무의 목질부, 어린 가지, 과병 및 잎의 저급알콜 불용성 추출물을 각각 투여한 시험군들은 약간의 감소가 보이나, 거의 유의적인 차이를 나타내지 않았다. 헛개나무 추출물을 투여한 시험군에서 체중감소가 거의 나타나지 않은 것은 당뇨 증상이 다소 가벼워졌기 때문인 것으로 생각된다.As a result, in the case of body weight, as shown in FIG. 8, the normal control group increased 43.3% compared to the original body weight, and the diabetes-induced control group decreased 13.9% on day 8, and lower alcohols of woody parts, young branches, fruits and leaves of larvae The test groups administered with each insoluble extract showed a slight decrease, but showed no significant difference. The reason that the weight loss was not shown in the test group administered with the bark extract is thought to be that the symptoms of diabetes are lighter.
한편, 사료섭취량에 있어서, 당뇨 유발 대조군은 정상 대조군보다 사료를 13.8 % 정도 더 소비했으나, 정상 대조군과 헛개나무 추출물을 투여한 시험군 사이에는 유의적인 차이가 나타나지 않았다(도 9).On the other hand, in the feed intake, the diabetes-induced control group consumed about 13.8% more of the feed than the normal control group, but there was no significant difference between the control group and the test group administered with the extract of the bark tree (FIG. 9).
결과적으로, 당뇨 유발 대조군에서는 많은 사료를 소비하고 체중은 감소하는 당뇨병의 전형적인 현상을 보인 반면, 헛개나무 부위별 추출물을 투여한 모든 시험군에서는 체중이 정상 수준으로 유지되므로 당뇨병 증세가 호전되었음을 알 수 있다.As a result, the diabetic control group showed a typical phenomenon of diabetes, which consumed a lot of feed and reduced weight, whereas all the test groups administered with extracts of the locusts maintained their normal weight, indicating that the symptoms of diabetes improved. have.
(2-3) 혈액화학 분석(2-3) Blood Chemistry Analysis
(1) 분석시료의 채취(1) Collection of Analytical Samples
STZ로 유발된 당뇨쥐에 헛개나무 부위별 저급알콜불용성 추출물을 투여한 지 10일 후 에테르 마취 하에 헤파린을 포함하는 모세관(capillary tube)으로 심장에서 혈액을 취한 후 4℃, 2,000 rpm에서 15분간 원심분리하여 혈장만을 취하여 캡튜브(cap tube)에 넣어 분석시까지 -20℃에서 냉동 보관하였다.After 10 days of administration of STZ-induced diabetic rats with low alcohol insoluble extracts, the blood was drawn from the heart with a capillary tube containing heparin under ether anesthesia, and then centrifuged at 4 ° C and 2,000 rpm for 15 minutes. Separately, only plasma was taken and placed in a cap tube and stored frozen at -20 ° C until analysis.
(2) 분석(2) analysis
당뇨로 인하여 야기되는 당질, 지질 및 단백질 대사의 변화를 통하여 헛개나무 목질부, 어린 가지, 과병 및 잎의 저급 알콜 추출물이 당뇨에 미치는 효과를 알아보고자 냉동 보관된 혈장을 해동시킨 후 혈장내의 포도당, 단백질, 알부민 및 요소(BUN)를 혈액생화학 분석기(Chiron/Diagnostics Express Plus (USA))를 이용해서 측정하였다. 그 결과는 각각 다음과 같다.To determine the effect of lower alcoholic extracts of bark wood, young branches, fruits and leaves on diabetes by changing the carbohydrate, lipid and protein metabolism caused by diabetes, thawed frozen plasma and glucose and protein in plasma , Albumin and urea (BUN) were measured using a blood biochemical analyzer (Chiron / Diagnostics Express Plus (USA)). The results are as follows.
혈장 포도당Plasma glucose
도 10에서 볼 수 있는 바와 같이, 당뇨 유발 대조군은 정상 대조군에 비해 169 %의 높은 혈장 포도당 수준을 나타내었다. 또한 헛개나무의 목질부, 어린 가지, 과병 및 잎의 저급알콜 불용성 추출물을 각각 투여한 시험군에서는 정상 대조군에 비해서 각각 70.8 %, 36.7 %, 125 % 및 67 %의 높은 수준을 보였지만 당뇨 유발 대조군에 비해서는 각각 36.6 %, 49.3 %, 16.4 % 및 38.0 %로 혈당 강하 효과를 나타내었다. 모든 헛개나무 부위별 추출물 투여군에서 혈당 강하 효과가 나타난 것으로 보아 혈당 강하 효과를 나타내는 성분이 헛개나무의 각 부위에 존재할 것으로 추정된다. STZ은 특히 β-세포에서 절대적인 인슐린 부족을 유발하기보다는 초기단계에서 포도당에 대한 신속한 인슐린 분비 반응을 손상시켜 고혈당증을 유발한다. 따라서 위와 같은 현저한 혈당강하 효과는 이들 헛개나무 부위별 추출물의 투여에 의해 포도당에 대한 인슐린의 감수성이 개선되었거나 손상된 β-세포의 기능이 신속하게 회복되어 나타난 것으로 추정된다.As can be seen in Figure 10, the diabetes-induced control group showed a higher plasma glucose level of 169% compared to the normal control group. In addition, the test group administered low alcohol insoluble extracts of woody, young branches, fruits and leaves of the larvae showed higher levels of 70.8%, 36.7%, 125% and 67%, respectively, than the control group. Were 36.6%, 49.3%, 16.4% and 38.0%, respectively. The hypoglycemic effect was observed in the extract-administered groups of all the larvae, and it is estimated that components exhibiting the hypoglycemic effect existed in each site of the larvae. STZ causes hyperglycemia by impairing the rapid insulin secretion response to glucose in the early stages rather than causing absolute insulin deficiency, particularly in β-cells. Therefore, such a significant hypoglycemic effect may be due to the improvement of insulin sensitivity to glucose or the impaired function of β-cells rapidly by administration of the extracts of the locusts.
혈장 단백질 및 알부민Plasma Proteins and Albumin
혈장 단백질 및 알부민 농도는 헛개나무 부위별 저급알콜 불용성 추출물을 투여한 시험군에서 당뇨 유발 대조군에 비해 유의적으로 상승한 것으로 나타났다(도 11 및 12). 이 결과는 헛개나무 부위별 저급알콜 불용성 추출물이 당뇨 유발시 감소하는 혈장내 알부민과 인체생리활성에 필요한 단백질의 생성을 촉진시켜 당뇨치료에 도움을 주는 것을 의미한다.Plasma protein and albumin concentrations were significantly increased in the test group administered the low alcohol insoluble extract of each part of the bark tree compared to the diabetes-induced control group (FIGS. 11 and 12). This result means that the lower alcohol insoluble extract of each part of the bark tree promotes the production of albumin and protein necessary for physiological physiological activity, which is decreased during diabetes-induced diabetes.
요소(Urea) 함량Urea Content
도 13에서 볼 수 있는 바와 같이, 혈장 요소 농도는 정상 대조군에 비해 당뇨 유발 대조군과 헛개나무 목부, 어린 가지, 과병 및 잎 추출물 투여 시험군에서 각각 122.3 %, 45.35 %, 68.3 %, 75.5 % 및 23.5 % 높게 나타났으나, 헛개나무 부위별 추출물 투여 시험군에서는 당뇨 유발 대조군에 비해 각각 35.3 %, 24.3 %, 21.0 % 및 44.5 % 감소한 것으로 나타나, 당뇨병이 유발됨으로써 증가하는 요소량이 헛개나무 추출물의 투여에 의해 감소한 것으로 확인되었다. 이 결과로부터 헛개나무 추출물이 당뇨병으로 인해 야기되는 요소 증가 증상을 해소시킴을 알 수 있다.As can be seen in Figure 13, plasma urea concentrations were 122.3%, 45.35%, 68.3%, 75.5%, and 23.5 in the diabetic-induced control group and the rat bark, young branches, fruit and leaf extract administration test groups, respectively, compared to the normal control group. However, in the test administration group of the extracts of the larvae, the percentage of urea increased by 35.3%, 24.3%, 21.0% and 44.5%, respectively, compared to the diabetes-induced control group. It was confirmed to decrease by. From this result, it can be seen that the liana extracts resolve the symptoms of increased urea caused by diabetes.
헛개나무의 저급알콜 불용성 추출물 및/또는 이로부터 분리된 다당체 분획을 유효성분으로 하고 약학적으로 허용되는 담체를 포함하는 본 발명의 약학 조성물, 및 헛개나무 저급알콜 불용성 추출물을 유효성분으로 하고 식품학적으로 허용되는첨가제를 포함하는 본 발명의 건강보조 식품은 당뇨병의 예방 및 치료에 매우 유용하다.The pharmaceutical composition of the present invention comprising a lower alcohol insoluble extract and / or a polysaccharide fraction isolated therefrom as a active ingredient and a pharmaceutically acceptable carrier, and a lower alcohol insoluble extract as a active ingredient The dietary supplement of the present invention comprising an acceptable additive as is very useful for the prevention and treatment of diabetes.
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020057998A KR100417287B1 (en) | 2002-09-25 | 2002-09-25 | Composition for treating diabetes comprising a lower alcohol insoluble extract from hovenia dulcis thunberg. or a polysaccharide isolated therefrom |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020057998A KR100417287B1 (en) | 2002-09-25 | 2002-09-25 | Composition for treating diabetes comprising a lower alcohol insoluble extract from hovenia dulcis thunberg. or a polysaccharide isolated therefrom |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100417287B1 true KR100417287B1 (en) | 2004-02-05 |
Family
ID=37319150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020057998A KR100417287B1 (en) | 2002-09-25 | 2002-09-25 | Composition for treating diabetes comprising a lower alcohol insoluble extract from hovenia dulcis thunberg. or a polysaccharide isolated therefrom |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100417287B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020149506A1 (en) | 2018-09-03 | 2020-07-23 | 한국식품연구원 | Food composition, for alleviating diabetes, comprising omija and bean juice, and preparation method thereof |
KR20210027721A (en) * | 2019-09-02 | 2021-03-11 | 박무순 | Pharmaceutical composition comprising the extract of medicinal or edible natural products as an effective component for prevention or treatment of diabetes and health functional food comprising the same |
KR20210050034A (en) | 2019-10-25 | 2021-05-07 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of diabetes mellitus |
KR20230045344A (en) | 2021-09-28 | 2023-04-04 | 농업회사법인 주식회사 장수식품 | A composition for lowering blood glucose level or for use of antioxidant comprising fermented thistle and a composition for improving of diabetes mellitus containing fermented thistle |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990037871A (en) * | 1999-02-08 | 1999-05-25 | 장철수 | Beverage for Curing Hangover and Manufacturing Method thereof |
-
2002
- 2002-09-25 KR KR1020020057998A patent/KR100417287B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990037871A (en) * | 1999-02-08 | 1999-05-25 | 장철수 | Beverage for Curing Hangover and Manufacturing Method thereof |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020149506A1 (en) | 2018-09-03 | 2020-07-23 | 한국식품연구원 | Food composition, for alleviating diabetes, comprising omija and bean juice, and preparation method thereof |
KR20210027721A (en) * | 2019-09-02 | 2021-03-11 | 박무순 | Pharmaceutical composition comprising the extract of medicinal or edible natural products as an effective component for prevention or treatment of diabetes and health functional food comprising the same |
KR102239159B1 (en) | 2019-09-02 | 2021-04-13 | 박무순 | Pharmaceutical composition comprising the extract of medicinal or edible natural products as an effective component for prevention or treatment of diabetes and health functional food comprising the same |
KR20210050034A (en) | 2019-10-25 | 2021-05-07 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of diabetes mellitus |
KR20230045344A (en) | 2021-09-28 | 2023-04-04 | 농업회사법인 주식회사 장수식품 | A composition for lowering blood glucose level or for use of antioxidant comprising fermented thistle and a composition for improving of diabetes mellitus containing fermented thistle |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090142425A1 (en) | Physiologically active composition | |
Arika et al. | In vivo antidiabetic activity of the aqueous leaf extract of Croton macrostachyus in alloxan induced diabetic mice | |
KR102132655B1 (en) | Composition containing chrysanthemum zawadskii extract | |
BRPI0708825A2 (en) | extracts and methods comprising species of ganoderma | |
CN107412721B (en) | Blood sugar-reducing bitter gourd polypeptide compound capsule and preparation method thereof | |
US20040058016A1 (en) | Lower alcohol-insoluble extract of hovenia dulcis var koreana nakai, a polysaccharide isolated therefrom and an antihepatotoxic composition containing same | |
KR100417287B1 (en) | Composition for treating diabetes comprising a lower alcohol insoluble extract from hovenia dulcis thunberg. or a polysaccharide isolated therefrom | |
US9173916B2 (en) | Method of preparing a muscadine pomace extract | |
KR20200145757A (en) | A composition for preventing, improving or treating alcoholic gastritis comprising fraction of Apios Americana tuber extract and a method for preparing the same | |
KR100403720B1 (en) | Lower alcohol insoluble extract and a polysaccharide therein isolated from the young branches of hovenia dulcis thunb. having antihepatotoxic, anti-hangover and anti-fatigue activity and composition containing same | |
KR102381856B1 (en) | HEALTH FUNCTIONAL FOOD COMPOSITION COMPRISING Hovenia dulcis PEDICEL EXTRACT AS AN EFFECTIVE INGREDIENT AND METHOD FOR VERIFING FUNCTION OF THE SAME | |
CN110483657B (en) | Chinese lobelia homogeneous polysaccharide and preparation method and application thereof | |
KR101449670B1 (en) | Composition for preventing or treating diabetes or complications of diabetes mellitus comprising Rhododendron mucronulatum for. albiflorum extract | |
CA2904636C (en) | Method of preparing a muscadine pomace extract | |
KR102003354B1 (en) | Composition comprising Spike mulberry mistletoe extract for treating diabetes | |
KR100543405B1 (en) | Composition comprising the extract of Allium victorialis L. var. platyphyllum for treating or preventing diabetes mellitus | |
KR20100089910A (en) | Composition comprising the mixed herbal extract for preventing and treating hyperlipidemia and diabetic hyperlipidemia | |
KR100729213B1 (en) | Exo-biopolymer isolated from submerged mycelial culture of Grifola frondosa increasing immune activity | |
KR20130056940A (en) | Compositions for preventing and treating diabetes or diabetic complications comprising extracts of acer tegmentosum maximowoca and magnolia officinalis rehd. et wils | |
KR100757220B1 (en) | Composition comprising the extract of salicis radicis cortex for immune activity | |
KR100562525B1 (en) | Composition containing a polysaccharide fraction isolated from cordyceps militaris for preventing and treating diabetes mellitus | |
KR100464209B1 (en) | Health food containing lower alcohol insoluble extract and a polysaccharide therein isolated from hovenia dulcis nakai for enhancing athletic ability | |
KR100523326B1 (en) | A Method for Extracting Antidiabetically Active Extract from Aralia elata Seemann and the Extract | |
Ge et al. | Recent advances on chemical constituents from Dioscorea opposita and their biological activities | |
Ali et al. | CHEMICAL ANALYSIS, ANTIOXIDANTS AND SUGARS IN WHITE MULBERRY FRUITS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130121 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140120 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20150120 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160720 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170516 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20180309 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20190121 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20200120 Year of fee payment: 17 |